Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Mesoblast (MESO)

Mesoblast Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MESO
DateTimeSourceHeadlineSymbolCompany
30/04/202402:05GlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
26/03/202413:25AllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
26/03/202402:34GlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
13/03/202423:30GlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
10/03/202423:54GlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
28/02/202422:57GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
26/02/202412:00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
15/02/202400:46GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
01/02/202402:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
31/01/202402:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
19/01/202400:28Dow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
18/01/202423:36GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
16/01/202411:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
05/01/202402:57Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
22/12/202322:13Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
26/11/202323:56GlobeNewswire Inc.Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
22/11/202318:35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
22/11/202318:35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
21/11/202323:32GlobeNewswire Inc.Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDNASDAQ:MESOMesoblast Limited
31/10/202300:04GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023NASDAQ:MESOMesoblast Limited
26/09/202311:18GlobeNewswire Inc.Jane Bell AM Appointed Chair of Mesoblast Audit and Risk CommitteeNASDAQ:MESOMesoblast Limited
21/09/202308:30GlobeNewswire Inc.Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalNASDAQ:MESOMesoblast Limited
06/09/202311:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MESOMesoblast Limited
31/08/202300:07GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023NASDAQ:MESOMesoblast Limited
29/08/202312:00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
04/08/202314:03Dow Jones NewsMesoblast ADSs Plunge Premarket on Latest FDA RejectionNASDAQ:MESOMesoblast Limited
04/08/202301:10GlobeNewswire Inc.Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenNASDAQ:MESOMesoblast Limited
31/07/202301:31GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023NASDAQ:MESOMesoblast Limited
06/06/202313:46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
05/06/202301:21GlobeNewswire Inc.Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

Your Recent History

Delayed Upgrade Clock